Phase II Dog Lymphoma Trial Confirms Monepantel Clinical Benefit
171211_Lymphoma Trial Result_(clean)
PharmAust Raises $1.873m via an Oversubscribed Placement
171206_Capital Raise
Results of AGM 2017
171129_Results of AGM
Trading Halt Request
171201_Trading Halt Request
AGM Presentation 2017
171129_ AGM Presentation
PharmAust Identifies New Proprietary Monepantel-related Compounds With Greater Anti-cancer Activity
171123_Improved potency of MPL analogues_clean
PharmAust secures patent in US for new portfolio of anticancer drugs
17113_MPL4_US_New drugs patented for cancer_(clean)
Dogs needed to help evaluate a promising new anti-cancer drug
New cancer treatment available for dogs with lymphoma